Source: MGC Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) indicates CimetrA has a wide-ranging application as an anti-inflammatory treatment
  • Results from a study demonstrated the product could be used for more than purely the treatment of COVID-19, which had been the primary focus of clinical trials to date
  • The study was undertaken by an Israeli research organisation and found CimetrA could be used for the treatment of rheumatoid arthritis, inflammatory bowel disease and asthma
  • Following the study, MGC Pharma says it plans to further explore aspects of CimetrA’s profile and begin planning the next phases of its clinical development
  • MGC Pharmaceuticals ends the day 5.88 per cent in the green to close at 1.8 cents

MGC Pharmaceuticals (MXC) has indicated CimetrA has a wide-ranging application as an anti-inflammatory treatment.

The company today announced an update on its pre-clinical in-vitro study for its proprietary investigation medicinal product, CimetrA.

Results from the study indicated CimetrA could be used for more than purely the treatment of symptoms of COVID-19, which had been the primary focus of clinical trials to date.

The study was undertaken by Israeli contract research organisation, Science in Action, and built on previous studies commissioned by MGC Pharma.

The study found that CimetrA moderates the body’s release of pro-inflammatory cytokines by affecting their gene expression and transcription factors.

Specifically, the study demonstrated the blocking of the pro-inflammatory cytokine related to rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis and chronic obstructive pulmonary disease.

Following the study, MGC Pharma said it plans to further explore aspects of CimetrA’s profile and begin planning the next phases of its clinical development.

Roby Zomer, Co-Founder and Managing Director of MGC Pharmaceuticals, said the announcement is a big leap forward, with more conditions potentially being treatable with the drug.

“Its anti-inflammatory profile means that it could transform the lives of thousands of patients, and it is particularly reassuring that these latest results confirm the findings of previous studies,” he said.

“In light of these results, MGC is in the process of designing the next phase of CimetrA’s clinical pathway and will keep everyone updated.”

MGC Pharmaceuticals has ended the day 5.88 per cent in the green to close at 1.8 cents.

MXC by the numbers
More From The Market Herald
MetalsGrove Mining (ASX:MGA) - Managing Director, Sean Sivasamy

" MetalsGrove Mining (ASX:MGA) begins soil sampling at Upper Coondina

MetalsGrove Mining (ASX:MGA) has begun a soil sampling program at its Upper Coondina lithium project in…
Bellavista Resources (ASX:BVR) - Non Executive Chairman, Mel Ashton

" Bellavista Resources (ASX:BVR) commissions second rig for Brumby, WA

Bellavista Resources (ASX:BVR) has commissioned a second rig to begin drilling at its Brumby zinc-silver-copper project…

" Sky Metals (ASX:SKY) encounters further tin mineralisation at Tallebung, NSW

Sky Metals (ASX:SKY) has reported further tin mineralisation at its Tallebung tin project in New South…
Spectur (ASX:SP3) - Managing Director, Gerard Dyson

" Spectur (ASX:SP3) raises $1.15m in SPP

Spectur (ASX:SP3) has raised $1.15 million through a security purchase plan (SPP) and shortfall offer.